DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Shaw AT, Gandhi L, Gadgeel S. et al.
study investigators. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Lancet Oncol 2016;
17 (02) 234-242
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.